Robin K Kelley
Overview
Explore the profile of Robin K Kelley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
5874
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Singal A, Reddy K, Colombo M, Morris H, Mospan A, Cabrera R, et al.
J Viral Hepat
. 2025 Jan;
32(2):e14056.
PMID: 39822115
Direct-acting antiviral (DAA) therapy is associated with a significant reduction in hepatocellular carcinoma (HCC) incidence among patients with cirrhosis, but data are conflicting about the risk of recurrence following DAA...
2.
Turnham R, Pitea A, Jang G, Xu Z, Lim H, Choi A, et al.
Cancer Res
. 2024 Dec;
85(4):660-674.
PMID: 39652575
Hepatitis B virus (HBV) infections promote liver cancer initiation by inducing inflammation and cellular stress. Despite a primarily indirect effect on oncogenesis, HBV is associated with a recurrent genomic phenotype...
3.
Li M, Hannan L, Goyal L, Bocobo A, Parks A, Bauer K, et al.
Ther Adv Med Oncol
. 2024 Nov;
16:17588359241297085.
PMID: 39563717
Background: Early changes in alpha-fetoprotein (AFP) are a promising surrogate endpoint for systemic treatment outcomes in hepatocellular carcinoma (HCC). Objectives: We sought to investigate the utility of AFP response across...
4.
Zeme E, Van Loon K, Kelley R, Gordan J
J Clin Oncol
. 2024 Aug;
42(27):3170-3176.
PMID: 39102636
Journal Journal of Clinical Oncology
5.
Vijay V, Karisani N, Shi L, Hung Y, Vu P, Kattel P, et al.
bioRxiv
. 2024 Jul;
PMID: 39026794
Biliary tract cancers (BTCs) are a group of deadly malignancies encompassing intrahepatic and extrahepatic cholangiocarcinoma, gallbladder carcinoma, and ampullary carcinoma. Here, we present the integrative analysis of 63 BTC cell...
6.
Hsu B, Driscoll J, Tateno C, Mattis A, Kelley R, Willenbring H
Gastroenterology
. 2024 Jun;
167(5):1029-1032.e7.
PMID: 38866344
No abstract available.
7.
Azad N, Hu Z, Sahin I, Iyer R, Aranha O, Hochster H, et al.
Future Oncol
. 2024 Jun;
20(30):2241-2248.
PMID: 38861293
Treatment options for patients with biliary tract cancer are limited, and the prognosis is poor. CTX-009, a novel bispecific antibody targeting both DLL4 and VEGF-A, has demonstrated antitumor activity in...
8.
Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A, et al.
J Hepatol
. 2024 May;
81(4):e176-e177.
PMID: 38729354
No abstract available.
9.
Vogel A, Kelley R, Johnson P, Merle P, Yau T, Kudo M, et al.
Liver Cancer
. 2023 Oct;
12(4):372-391.
PMID: 37817754
Introduction: We conducted a systematic literature review to assess the utility of liver function assessments for predicting disease prognosis and response to systemic anticancer therapy in patients with advanced hepatocellular...
10.
Xie E, Yeo Y, Scheiner B, Zhang Y, Hiraoka A, Tantai X, et al.
JAMA Oncol
. 2023 Aug;
9(10):1423-1431.
PMID: 37615958
Importance: Immune checkpoint inhibitors (ICIs) are increasingly used in patients with advanced hepatocellular carcinoma (HCC). However, data on ICI therapy in patients with advanced HCC and impaired liver function are...